1Even-Sapir E,Parag Y,Lerman H,et al.Detection of recurrence in patients with rectal cancer:PET/CT aner abdominoperineal or anterior resection[J].Radiology,2004,232(3):815-822.
2Lonneux M,Reffad AM,Detry R,et al.FDG-PET improves the staging and selection of patients with recurrent colorectal cancer[J].Eur J Nucl Med Mol Imaging,2002,29(7):915-921.
4Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med,1995, 36: 1811-1817.
5Maisey MN, Wahl RL, Barrington SF. Atlas of clinical positron emission tomography. London: Arnold, 1999. 215-234.
8Meta J,Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer:the referring physician's perspective[J]. J Nucl Med, 2001,42(4) : 586-590.
9Khan S, Tan YM, John A, et al. An audit of fusion CT-PET in the management of colorectal liver metastases [ J ]. Eur J Surg Oncol, 2006, 32(5):564-567.
10Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography(PET) [J]. Eur J Cancer, 2001,37(7): 862-869.
